Vaccine-induced myeloid cell population dampens protective immunity to SIV

Yongjun Sui, Alison Hogg, Yichuan Wang, Blake Frey, Huifeng Yu, Zheng Xia, David Venzon, Katherine McKinnon, Jeremy Smedley, Mercy Gathuka, Dennis Klinman, Brandon F. Keele, Sol Langermann, Linda Liu, Genoveffa Franchini, Jay A. Berzofsky

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Vaccines are largely evaluated for their ability to promote adaptive immunity, with little focus on the induction of negative immune regulators. Adjuvants facilitate and enhance vaccine-induced immune responses and have been explored for mediating protection against HIV. Using a regimen of peptide priming followed by a modified vaccinia Ankara (MVA) boost in a nonhuman primate model, we found that an SIV vaccine incorporating molecular adjuvants mediated partial protection against rectal SIVmac251 challenges. Animals treated with vaccine and multiple adjuvants exhibited a reduced viral load (VL) compared with those treated with vaccine only. Surprisingly, animals treated with adjuvant alone had reduced VLs that were comparable to or better than those of the vaccine-treated group. VL reduction was greatest in animals with the MHC class I allele Mamu-A*01 that were treated with adjuvant only and was largely dependent on CD8+ T cells. Early VLs correlated with Ki67+CCR5+CD4+ T cell frequency, while set-point VL was associated with expansion of a myeloid cell population that was phenotypically similar to myeloid-derived suppressor cells (MDSCs) and that suppressed T cell responses in vitro. MDSC expansion occurred in animals receiving vaccine and was not observed in the adjuvant-only group. Collectively, these results indicate that vaccine-induced MDSCs inhibit protective cellular immunity and suggest that preventing MDSC induction may be critical for effective AIDS vaccination.

Original languageEnglish (US)
Pages (from-to)2538-2549
Number of pages12
JournalJournal of Clinical Investigation
Volume124
Issue number6
DOIs
StatePublished - Jun 2 2014
Externally publishedYes

Fingerprint

Myeloid Cells
Immunity
Vaccines
Population
Viral Load
T-Lymphocytes
SAIDS Vaccines
Vaccinia
Adaptive Immunity
Cellular Immunity
Primates
Vaccination
Acquired Immunodeficiency Syndrome
Alleles
HIV
Peptides
Myeloid-Derived Suppressor Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sui, Y., Hogg, A., Wang, Y., Frey, B., Yu, H., Xia, Z., ... Berzofsky, J. A. (2014). Vaccine-induced myeloid cell population dampens protective immunity to SIV. Journal of Clinical Investigation, 124(6), 2538-2549. https://doi.org/10.1172/JCI73518

Vaccine-induced myeloid cell population dampens protective immunity to SIV. / Sui, Yongjun; Hogg, Alison; Wang, Yichuan; Frey, Blake; Yu, Huifeng; Xia, Zheng; Venzon, David; McKinnon, Katherine; Smedley, Jeremy; Gathuka, Mercy; Klinman, Dennis; Keele, Brandon F.; Langermann, Sol; Liu, Linda; Franchini, Genoveffa; Berzofsky, Jay A.

In: Journal of Clinical Investigation, Vol. 124, No. 6, 02.06.2014, p. 2538-2549.

Research output: Contribution to journalArticle

Sui, Y, Hogg, A, Wang, Y, Frey, B, Yu, H, Xia, Z, Venzon, D, McKinnon, K, Smedley, J, Gathuka, M, Klinman, D, Keele, BF, Langermann, S, Liu, L, Franchini, G & Berzofsky, JA 2014, 'Vaccine-induced myeloid cell population dampens protective immunity to SIV', Journal of Clinical Investigation, vol. 124, no. 6, pp. 2538-2549. https://doi.org/10.1172/JCI73518
Sui, Yongjun ; Hogg, Alison ; Wang, Yichuan ; Frey, Blake ; Yu, Huifeng ; Xia, Zheng ; Venzon, David ; McKinnon, Katherine ; Smedley, Jeremy ; Gathuka, Mercy ; Klinman, Dennis ; Keele, Brandon F. ; Langermann, Sol ; Liu, Linda ; Franchini, Genoveffa ; Berzofsky, Jay A. / Vaccine-induced myeloid cell population dampens protective immunity to SIV. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 6. pp. 2538-2549.
@article{f2010e3f1eff425a88908725f077315f,
title = "Vaccine-induced myeloid cell population dampens protective immunity to SIV",
abstract = "Vaccines are largely evaluated for their ability to promote adaptive immunity, with little focus on the induction of negative immune regulators. Adjuvants facilitate and enhance vaccine-induced immune responses and have been explored for mediating protection against HIV. Using a regimen of peptide priming followed by a modified vaccinia Ankara (MVA) boost in a nonhuman primate model, we found that an SIV vaccine incorporating molecular adjuvants mediated partial protection against rectal SIVmac251 challenges. Animals treated with vaccine and multiple adjuvants exhibited a reduced viral load (VL) compared with those treated with vaccine only. Surprisingly, animals treated with adjuvant alone had reduced VLs that were comparable to or better than those of the vaccine-treated group. VL reduction was greatest in animals with the MHC class I allele Mamu-A*01 that were treated with adjuvant only and was largely dependent on CD8+ T cells. Early VLs correlated with Ki67+CCR5+CD4+ T cell frequency, while set-point VL was associated with expansion of a myeloid cell population that was phenotypically similar to myeloid-derived suppressor cells (MDSCs) and that suppressed T cell responses in vitro. MDSC expansion occurred in animals receiving vaccine and was not observed in the adjuvant-only group. Collectively, these results indicate that vaccine-induced MDSCs inhibit protective cellular immunity and suggest that preventing MDSC induction may be critical for effective AIDS vaccination.",
author = "Yongjun Sui and Alison Hogg and Yichuan Wang and Blake Frey and Huifeng Yu and Zheng Xia and David Venzon and Katherine McKinnon and Jeremy Smedley and Mercy Gathuka and Dennis Klinman and Keele, {Brandon F.} and Sol Langermann and Linda Liu and Genoveffa Franchini and Berzofsky, {Jay A.}",
year = "2014",
month = "6",
day = "2",
doi = "10.1172/JCI73518",
language = "English (US)",
volume = "124",
pages = "2538--2549",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Vaccine-induced myeloid cell population dampens protective immunity to SIV

AU - Sui, Yongjun

AU - Hogg, Alison

AU - Wang, Yichuan

AU - Frey, Blake

AU - Yu, Huifeng

AU - Xia, Zheng

AU - Venzon, David

AU - McKinnon, Katherine

AU - Smedley, Jeremy

AU - Gathuka, Mercy

AU - Klinman, Dennis

AU - Keele, Brandon F.

AU - Langermann, Sol

AU - Liu, Linda

AU - Franchini, Genoveffa

AU - Berzofsky, Jay A.

PY - 2014/6/2

Y1 - 2014/6/2

N2 - Vaccines are largely evaluated for their ability to promote adaptive immunity, with little focus on the induction of negative immune regulators. Adjuvants facilitate and enhance vaccine-induced immune responses and have been explored for mediating protection against HIV. Using a regimen of peptide priming followed by a modified vaccinia Ankara (MVA) boost in a nonhuman primate model, we found that an SIV vaccine incorporating molecular adjuvants mediated partial protection against rectal SIVmac251 challenges. Animals treated with vaccine and multiple adjuvants exhibited a reduced viral load (VL) compared with those treated with vaccine only. Surprisingly, animals treated with adjuvant alone had reduced VLs that were comparable to or better than those of the vaccine-treated group. VL reduction was greatest in animals with the MHC class I allele Mamu-A*01 that were treated with adjuvant only and was largely dependent on CD8+ T cells. Early VLs correlated with Ki67+CCR5+CD4+ T cell frequency, while set-point VL was associated with expansion of a myeloid cell population that was phenotypically similar to myeloid-derived suppressor cells (MDSCs) and that suppressed T cell responses in vitro. MDSC expansion occurred in animals receiving vaccine and was not observed in the adjuvant-only group. Collectively, these results indicate that vaccine-induced MDSCs inhibit protective cellular immunity and suggest that preventing MDSC induction may be critical for effective AIDS vaccination.

AB - Vaccines are largely evaluated for their ability to promote adaptive immunity, with little focus on the induction of negative immune regulators. Adjuvants facilitate and enhance vaccine-induced immune responses and have been explored for mediating protection against HIV. Using a regimen of peptide priming followed by a modified vaccinia Ankara (MVA) boost in a nonhuman primate model, we found that an SIV vaccine incorporating molecular adjuvants mediated partial protection against rectal SIVmac251 challenges. Animals treated with vaccine and multiple adjuvants exhibited a reduced viral load (VL) compared with those treated with vaccine only. Surprisingly, animals treated with adjuvant alone had reduced VLs that were comparable to or better than those of the vaccine-treated group. VL reduction was greatest in animals with the MHC class I allele Mamu-A*01 that were treated with adjuvant only and was largely dependent on CD8+ T cells. Early VLs correlated with Ki67+CCR5+CD4+ T cell frequency, while set-point VL was associated with expansion of a myeloid cell population that was phenotypically similar to myeloid-derived suppressor cells (MDSCs) and that suppressed T cell responses in vitro. MDSC expansion occurred in animals receiving vaccine and was not observed in the adjuvant-only group. Collectively, these results indicate that vaccine-induced MDSCs inhibit protective cellular immunity and suggest that preventing MDSC induction may be critical for effective AIDS vaccination.

UR - http://www.scopus.com/inward/record.url?scp=84902134160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902134160&partnerID=8YFLogxK

U2 - 10.1172/JCI73518

DO - 10.1172/JCI73518

M3 - Article

C2 - 24837435

AN - SCOPUS:84902134160

VL - 124

SP - 2538

EP - 2549

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -